Earendil Labs Partners WuXi Biologics on Antibody Pipeline

Earendil Labs has entered into a strategic collaboration with WuXi Biologics to accelerate the development and manufacturing of a portfolio of next-generation biologics, including bispecific and multispecific antibodies as well as antibody-drug conjugates (ADCs). The partnership aims to advance therapies targeting autoimmune diseases, cancer, and other serious conditions.

Under the agreement, WuXi Biologics will provide comprehensive, end-to-end services spanning biologics development and manufacturing. These include cell line development, process optimization, bioassay development, drug product formulation, and current Good Manufacturing Practice (GMP) production. The collaboration is designed to streamline development timelines, improve chemistry, manufacturing, and controls (CMC) execution, and enable scalable global clinical programs for Earendil Labs’ pipeline.

The deal leverages WuXi Biologics’ extensive experience in handling complex biologics. By 2025, the company had advanced 945 projects through its integrated contract research, development, and manufacturing organization (CRDMO) platform, with bispecific and multispecific antibodies emerging as one of the fastest-growing segments. Its technology platforms—including WuXia™ TrueSite for targeted cell line integration and WuXiHigh™ for high-throughput formulation—are expected to play a key role in supporting the collaboration. Additional capabilities, such as high-dose and subcutaneous delivery systems, including hyaluronidase-based co-formulation and large-volume device solutions, further strengthen its offering.

Executives from both companies emphasized the strategic importance of combining advanced technologies and expertise. Jian Peng, CEO of Earendil Labs, said the partnership would enhance the company’s ability to advance its pipeline with greater efficiency and precision. He highlighted that integrating Earendil’s AI-driven protein engineering capabilities with WuXi Biologics’ development and manufacturing expertise could accelerate progress toward clinical milestones and ultimately improve patient outcomes.

Zhenping Zhu, President and co-CEO of Earendil Labs, noted that the company has built a competitive and diversified pipeline over the past three years. He added that the collaboration strengthens its capacity to translate AI-driven innovation into high-quality clinical and commercial assets, positioning the company for long-term growth in the biologics space.

Chris Chen, CEO of WuXi Biologics, described the agreement as an opportunity to support a cutting-edge biotech partner. He emphasized that WuXi’s global capabilities and proven track record in complex biologics would help accelerate development and ensure scalable manufacturing, ultimately bringing innovative therapies to patients worldwide.

The partnership reflects a broader trend in the biopharmaceutical industry, where collaborations between AI-driven biotech firms and established manufacturing organizations are becoming increasingly important to speed up innovation and meet global demand for advanced therapeutics.